ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average of $5.02

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $5.02 and traded as high as $5.13. ImmuCell shares last traded at $5.02, with a volume of 3,187 shares traded.

ImmuCell Trading Down 0.6 %

The company has a fifty day moving average price of $5.16 and a two-hundred day moving average price of $5.02. The company has a current ratio of 2.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.42.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share for the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%. The firm had revenue of $5.10 million for the quarter.

Institutional Trading of ImmuCell

Institutional investors have recently bought and sold shares of the stock. Mission Wealth Management LP acquired a new stake in ImmuCell in the 3rd quarter valued at $53,000. Vanguard Group Inc. boosted its stake in ImmuCell by 22.2% in the 1st quarter. Vanguard Group Inc. now owns 204,325 shares of the biotechnology company’s stock valued at $1,972,000 after buying an additional 37,081 shares in the last quarter. Cresset Asset Management LLC boosted its stake in ImmuCell by 4.2% in the 1st quarter. Cresset Asset Management LLC now owns 100,506 shares of the biotechnology company’s stock valued at $518,000 after buying an additional 4,080 shares in the last quarter. Morgan Stanley boosted its stake in ImmuCell by 3.8% in the 4th quarter. Morgan Stanley now owns 76,874 shares of the biotechnology company’s stock valued at $469,000 after buying an additional 2,800 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in ImmuCell by 175.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 62,170 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 39,591 shares in the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.